T1	PROC 46 69	Estudio de continuación
T2	DISO 87 90	CET
#1	AnnotatorNotes T2	C0041341; tuberous sclerosis complex; Neoplastic Process
T3	DISO 93 111	crisis epilépticas
#2	AnnotatorNotes T3	C4317109; Epileptic Seizures; Disease or Syndrome
T4	PROC 177 205	continuación del tratamiento
#3	AnnotatorNotes T4	C2091305; continue current medication; Therapeutic or Preventive Procedure
T5	DISO 423 426	CET
#4	AnnotatorNotes T5	C0041341; tuberous sclerosis complex; Neoplastic Process
T6	PROC 296 371	Estudio de continuación, abierto, multicéntrico, de seguridad a largo plazo
T7	DISO 390 421	complejo de esclerosis tuberosa
T8	DISO 430 448	crisis epilépticas
#5	AnnotatorNotes T8	C4317109; Epileptic Seizures; Disease or Syndrome
T9	DISO 721 724	CET
#6	AnnotatorNotes T9	C0041341; tuberous sclerosis complex; Neoplastic Process
T10	PROC 514 542	continuación del tratamiento
#7	AnnotatorNotes T10	C2091305; continue current medication; Therapeutic or Preventive Procedure
T11	DISO 643 661	Crisis epilépticas
#8	AnnotatorNotes T11	C4317109; Epileptic Seizures; Disease or Syndrome
T12	DISO 688 719	complejo de esclerosis tuberosa
T13	CHEM 867 877	everolimus
#9	AnnotatorNotes T13	C0541315; everolimus; Organic Chemical · Pharmacologic Substance
T14	PROC 976 987	tratamiento
#10	AnnotatorNotes T14	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T15	PROC 1091 1100	protocolo
#11	AnnotatorNotes T15	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T16	PROC 1266 1290;1315 1326	Consentimiento informado por escrito
#12	AnnotatorNotes T16	C0811741; Obtain informed written consent; Health Care Activity
T17	PROC 1450 1489	retirado permanentemente el tratamiento
#13	AnnotatorNotes T17	C0850893; stop medication; Therapeutic or Preventive Procedure (?)
T18	CHEM 1503 1513	everolimus
#14	AnnotatorNotes T18	C0541315; everolimus; Organic Chemical · Pharmacologic Substance
T19	CHEM 1546 1556	Everolimus
#15	AnnotatorNotes T19	C0541315; everolimus; Organic Chemical · Pharmacologic Substance
T20	DISO 1590 1593	CET
#16	AnnotatorNotes T20	C0041341; tuberous sclerosis complex; Neoplastic Process
T21	DISO 1596 1614	crisis epilépticas
#17	AnnotatorNotes T21	C4317109; Epileptic Seizures; Disease or Syndrome
T22	CHEM 1699 1709	everolimus
#18	AnnotatorNotes T22	C0541315; everolimus; Organic Chemical · Pharmacologic Substance
T23	PROC 1729 1756	tratamientos experimentales
#19	AnnotatorNotes T23	C0949266; Therapies, Investigational; Therapeutic or Preventive Procedure
T24	DISO 1795 1813	crisis epilépticas
#20	AnnotatorNotes T24	C4317109; Epileptic Seizures; Disease or Syndrome
T25	CHEM 1819 1843	fármacos antiepilépticos
T26	CHEM 1845 1849	AEDs
T27	DISO 1887 1905	crisis epilépticas
#21	AnnotatorNotes T27	C4317109; Epileptic Seizures; Disease or Syndrome
T28	CHEM 210 220	everolimus
#22	AnnotatorNotes T28	C0541315; everolimus; Organic Chemical · Pharmacologic Substance
T29	CHEM 547 557	everolimus
#23	AnnotatorNotes T29	C0541315; everolimus; Organic Chemical · Pharmacologic Substance
T30	CHEM 992 1002	everolimus
#24	AnnotatorNotes T30	C0541315; everolimus; Organic Chemical · Pharmacologic Substance
T31	PROC 1228 1239	tratamiento
#25	AnnotatorNotes T31	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T32	Date 13 17	2016
T33	LIVB 73 82	pacientes
#26	AnnotatorNotes T33	C0030705; Patients; Patient or Disabled Group
T34	LIVB 142 154	investigador
#27	AnnotatorNotes T34	C0035173; Research Personnel; Professional or Occupational Group
T35	Date 358 371	a largo plazo
T36	LIVB 376 385	pacientes
#28	AnnotatorNotes T36	C0030705; Patients; Patient or Disabled Group
T37	LIVB 479 491	investigador
#29	AnnotatorNotes T37	C0035173; Research Personnel; Professional or Occupational Group
T38	LIVB 756 765	Pacientes
#30	AnnotatorNotes T38	C0030705; Patients; Patient or Disabled Group
T39	Date 789 800	actualmente
T40	LIVB 924 933	Pacientes
#31	AnnotatorNotes T40	C0030705; Patients; Patient or Disabled Group
T41	Date 960 971	actualmente
T42	LIVB 1023 1035	investigador
#32	AnnotatorNotes T42	C0035173; Research Personnel; Professional or Occupational Group
T43	LIVB 1039 1048	Pacientes
#33	AnnotatorNotes T43	C0030705; Patients; Patient or Disabled Group
T44	LIVB 1143 1155	investigador
#34	AnnotatorNotes T44	C0035173; Research Personnel; Professional or Occupational Group
T45	LIVB 1160 1169	Pacientes
#35	AnnotatorNotes T45	C0030705; Patients; Patient or Disabled Group
T47	LIVB 1418 1427	Pacientes
#36	AnnotatorNotes T47	C0030705; Patients; Patient or Disabled Group
T50	LIVB 1576 1585	pacientes
#37	AnnotatorNotes T50	C0030705; Patients; Patient or Disabled Group
T51	LIVB 1668 1677	Pacientes
#38	AnnotatorNotes T51	C0030705; Patients; Patient or Disabled Group
T46	PROC 1242 1249	visitas
#39	AnnotatorNotes T46	C1512346; Patient Visit; Health Care Activity
A1	Status T18 History_of
#40	AnnotatorNotes T35	C0443252; Long-term; Temporal Concept
#41	AnnotatorNotes T7	C0041341; tuberous sclerosis complex; Neoplastic Process
#42	AnnotatorNotes T12	C0041341; tuberous sclerosis complex; Neoplastic Process
#43	AnnotatorNotes T25	C0003299; Antiepileptic Agents; Pharmacologic Substance
#44	AnnotatorNotes T26	C0003299; Antiepileptic Agents; Pharmacologic Substance
#45	AnnotatorNotes T39	C0521116; Current (present time); Temporal Concept 
#46	AnnotatorNotes T41	C0521116; Current (present time); Temporal Concept 
T48	Quantifier_or_Qualifier 1762 1771	aprobados
A2	Assertion T48 Negated
#47	AnnotatorNotes T48	C0205540; Approved; Qualitative Concept
T49	Neg_cue 1759 1761	no
R1	Negation Arg1:T49 Arg2:T48	
R2	Used_for Arg1:T28 Arg2:T4	
R3	Experiences Arg1:T33 Arg2:T2	
R4	Experiences Arg1:T33 Arg2:T3	
R5	Experiences Arg1:T33 Arg2:T4	
T52	Quantifier_or_Qualifier 112 124	refractarias
#48	AnnotatorNotes T52	C0205269; Unresponsive to Treatment; Functional Concept
R6	Has_Quantifier_or_Qualifier Arg1:T2 Arg2:T52	
R7	Has_Quantifier_or_Qualifier Arg1:T3 Arg2:T52	
T53	Quantifier_or_Qualifier 449 461	refractarias
#49	AnnotatorNotes T53	C0205269; Unresponsive to Treatment; Functional Concept
R8	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T53	
T54	Observation 235 259	finalización del estudio
#50	AnnotatorNotes T54	C2732579; Completion of clinical trial; Finding
R9	After Arg1:T4 Arg2:T54	
T55	Observation 572 596	finalización del estudio
#51	AnnotatorNotes T55	C2732579; Completion of clinical trial; Finding
R10	Used_for Arg1:T29 Arg2:T10	
R11	After Arg1:T10 Arg2:T55	
R12	Experiences Arg1:T36 Arg2:T7	
R13	Experiences Arg1:T36 Arg2:T5	
R14	Experiences Arg1:T36 Arg2:T8	
R15	Experiences Arg1:T36 Arg2:T10	
R16	Overlap Arg1:T7 Arg2:T8	
R17	Overlap Arg1:T5 Arg2:T8	
R18	Overlap Arg1:T2 Arg2:T3	
R19	Overlap Arg1:T6 Arg2:T35	
R20	Overlap Arg1:T11 Arg2:T12	
R21	Overlap Arg1:T11 Arg2:T9	
T56	Quantifier_or_Qualifier 662 674	refractarias
#52	AnnotatorNotes T56	C0205269; Unresponsive to Treatment; Functional Concept
R22	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T56	
T57	Observation 776 814	participando actualmente en el estudio
R23	Overlap Arg1:T57 Arg2:T39	
R24	Experiences Arg1:T38 Arg2:T13	
T58	Observation 890 919	cumplido todos sus requisitos
#53	AnnotatorNotes T58	C4329786; Eligibility Criteria Met By Subject; Finding
R25	Experiences Arg1:T40 Arg2:T14	
T59	Observation 947 959	beneficiando
R26	Experiences Arg1:T40 Arg2:T59	
T60	Observation 155 170	se beneficiarán
R27	Experiences Arg1:T33 Arg2:T60	
R28	Overlap Arg1:T60 Arg2:T4	
T61	Observation 492 507	se beneficiarán
R29	Experiences Arg1:T36 Arg2:T61	
R30	Overlap Arg1:T61 Arg2:T10	
R31	Overlap Arg1:T59 Arg2:T41	
R32	Used_for Arg1:T30 Arg2:T14	
R33	Overlap Arg1:T59 Arg2:T14	
T62	Observation 1053 1100	hayan cumplido con los requisitos del protocolo
A3	Status T62 History_of
A4	Status T58 History_of
T63	Observation 1180 1190	dispuestos
#54	AnnotatorNotes T63	C0600109; Willing; Finding (?)
T64	Observation 1202 1249	cumplir con los planes de tratamiento y visitas
T65	Quantifier_or_Qualifier 1250 1261	programadas
#55	AnnotatorNotes T65	C0205539; Scheduled - procedure status; Qualitative Concept
R34	Has_Quantifier_or_Qualifier Arg1:T46 Arg2:T65	
R35	Has_Quantifier_or_Qualifier Arg1:T45 Arg2:T63	
R36	Overlap Arg1:T63 Arg2:T31	
R37	Overlap Arg1:T63 Arg2:T46	
R40	Experiences Arg1:T47 Arg2:T17	
R41	Used_for Arg1:T18 Arg2:T17	
R42	Experiences Arg1:T50 Arg2:T19	
R43	Experiences Arg1:T50 Arg2:T20	
R44	Overlap Arg1:T20 Arg2:T21	
R45	Experiences Arg1:T50 Arg2:T21	
T66	Quantifier_or_Qualifier 1615 1627	refractarias
#56	AnnotatorNotes T66	C0205269; Unresponsive to Treatment; Functional Concept
R46	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T66	
T67	Quantifier_or_Qualifier 1562 1570	aprobado
#57	AnnotatorNotes T67	C0205540; Approved; Qualitative Concept
R47	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T67	
T68	Quantifier_or_Qualifier 1635 1646	reembolsado
R48	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T68	
R49	Experiences Arg1:T51 Arg2:T22	
R50	Combined_with Arg1:T22 Arg2:T23	
R51	Has_Quantifier_or_Qualifier Arg1:T23 Arg2:T48	
R52	Experiences Arg1:T51 Arg2:T24	
R53	Experiences Arg1:T51 Arg2:T25	
R54	Experiences Arg1:T51 Arg2:T26	
R55	Experiences Arg1:T51 Arg2:T27	
T69	Quantifier_or_Qualifier 1857 1867	permitidos
R56	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T69	
R57	Has_Quantifier_or_Qualifier Arg1:T26 Arg2:T69	
T70	CONC 1348 1357	inclusión
#58	AnnotatorNotes T70	C1512693; Inclusion; Qualitative Concept
R58	Before Arg1:T16 Arg2:T70	
T71	PROC 1364 1387	estudio de continuación
R59	Before Arg1:T16 Arg2:T71	
#59	AnnotatorNotes T60	C4049461; Unexpected beneficial therapeutic response; Finding (?)
#60	AnnotatorNotes T61	C4049461; Unexpected beneficial therapeutic response; Finding (?)
#61	AnnotatorNotes T69	C0205540; Approved; Qualitative Concept
#62	AnnotatorNotes T59	C4049461; Unexpected beneficial therapeutic response; Finding (?)
A5	Experiencer T33 Patient
A6	Experiencer T34 Other
A7	Experiencer T36 Patient
A8	Experiencer T37 Other
A9	Experiencer T38 Patient
A10	Experiencer T40 Patient
A11	Experiencer T42 Other
A12	Experiencer T44 Other
A13	Experiencer T43 Patient
A14	Experiencer T45 Patient
A15	Status T46 Future
A16	Experiencer T47 Patient
A17	Experiencer T50 Patient
A18	Experiencer T51 Patient
